Cinclus Pharma has lured back corporate venturing unit Recipharm Venture Fund for a $26.4m round that will fund a phase 2 study for its GERD therapy candidate.
Sweden-based biotech developer Cinclus Pharma has closed a SEK250m ($26.4m) financing round that included Recipharm Venture Fund, the strategic investment vehicle for pharmaceutical research and production services provider Recipharm.
Government-owned pension investment vehicle Fourth Swedish National Pension Fund also took part in the round, as did private investors Bengt Julander and Jonas Sjögren.
Cinclus is developing a clinical-stage drug called X842 to treat gastro-oesophageal reflux disease (GERD), a digestive disorder that occurs when stomach acids are regurgitated into the oesophagus,…
